We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

117 hedge funds and large institutions have $702M invested in Adamas Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 33 increasing their positions, 33 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more call options, than puts

Call options by funds: $8.83M | Put options by funds: $2.81M

129% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 17

79% more capital invested

Capital invested by funds: $391M → $702M (+$311M)

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

23% more funds holding

Funds holding: 95 → 117 (+22)

0% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 33

Holders
117
Holders Change
+22
Holders Change %
+23.16%
% of All Funds
2.65%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.14%
New
39
Increased
33
Reduced
33
Closed
17
Calls
$8.83M
Puts
$2.81M
Net Calls
+$6.02M
Net Calls Change
+$6.36M

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$47.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$35.2M
3
State Street
State Street
Massachusetts
+$30.8M
4
Deutsche Bank
Deutsche Bank
Germany
+$12.2M
5
DCM
Driehaus Capital Management
Illinois
+$6.06M

Top Sellers

Rank Fund Capital Flow
1
KA
Kerrisdale Advisers
Florida
-$19.1M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$18.5M
3
Millennium Management
Millennium Management
New York
-$16.9M
4
AC
Armistice Capital
New York
-$15.9M
5
Citadel Advisors
Citadel Advisors
Florida
-$13.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
NIP
51
Nicholas Investment Partners
California
$1.82M +$1.5M +53,598 New
Allianz Asset Management
52
Allianz Asset Management
Germany
$1.8M -$25.9K -929 -2%
Fidelity International
53
Fidelity International
Bermuda
$1.54M -$1.93M -69,262 -60%
Wells Fargo
54
Wells Fargo
California
$1.39M +$784K +28,061 +216%
UBS Group
55
UBS Group
Switzerland
$1.32M +$290K +10,377 +36%
BRWA
56
B. Riley Wealth Advisors
Florida
$1.31M +$1.08M +38,700 New
TCIM
57
TIAA CREF Investment Management
New York
$1.29M -$684K -24,502 -39%
MWVC
58
Morgens Waterfall Vintiadis & Co
New York
$1.25M +$1.03M +37,000 New
Fisher Asset Management
59
Fisher Asset Management
Washington
$1.24M -$2.09K -75 -0.2%
SCM
60
Sio Capital Management
New York
$1.19M +$977K +35,000 New
PAM
61
Private Asset Management
California
$1.15M – – –
Lazard Asset Management
62
Lazard Asset Management
New York
$1.13M +$931K +33,331 New
Voloridge Investment Management
63
Voloridge Investment Management
Florida
$1.07M +$883K +31,625 New
Charles Schwab
64
Charles Schwab
California
$1.04M +$89.9K +3,218 +12%
HP
65
Hikari Power
Japan
$1.02M – – –
OPPM
66
Opus Point Partners Management
New York
$1.02M – – –
Neuberger Berman Group
67
Neuberger Berman Group
New York
$915K +$754K +27,000 New
TA
68
Teachers Advisors
New York
$908K – – –
CS
69
Credit Suisse
Switzerland
$859K -$211K -7,543 -23%
ACM
70
Asymmetry Capital Management
California
$858K +$707K +25,311 New
AA
71
ALPS Advisors
Colorado
$855K +$85.7K +3,069 +14%
California State Teachers Retirement System (CalSTRS)
72
California State Teachers Retirement System (CalSTRS)
California
$798K +$3.49K +125 +0.5%
Squarepoint
73
Squarepoint
New York
$774K +$322K +11,532 +102%
New York State Common Retirement Fund
74
New York State Common Retirement Fund
New York
$755K +$117K +4,189 +23%
BRF
75
B. Riley Financial
California
$712K +$586K +21,000 New
1 2
3
4 5

ADMS Hedge Fund Activity: Q4 2017 in Review

117 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2017, worth a combined $702M — up 79% from $391M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new ADMS positions and 17 closed out — a net gain of 22 holders — while 33 added to existing stakes and 33 trimmed.

The largest buyer was Invesco, opening a new position worth an estimated $47.8M. The largest seller was Kerrisdale Advisers, cutting an estimated $19.1M.

  • 117 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2017, up from 95 in Q3 2017.
  • Funds reported $702M of Adamas Pharmaceuticals stock for Q4 2017, up 79% quarter-over-quarter.
  • 39 funds opened new Adamas Pharmaceuticals positions in Q4 2017 and 17 closed out, a net change of +22 holders.
  • The largest Adamas Pharmaceuticals buyer in Q4 2017 was Invesco, an estimated $47.8M added.
  • The largest Adamas Pharmaceuticals seller in Q4 2017 was Kerrisdale Advisers, an estimated $19.1M sold.

Based on aggregated 13F filings for Q4 2017.